Novartis has been streamlining its business since CEO Vas Narasimhan took over, and has continued that push with the divestment of three drugs to Recordati for $390 million upfront.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,